Skip to main
EHC
EHC logo

Encompass Health (EHC) Stock Forecast & Price Target

Encompass Health (EHC) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Encompass Health Corp has demonstrated a positive upward trend in revenue guidance, with the high-end of forecasts increasing from $1.065 billion to $1.090 billion for 2024, and from $910 million to $950 million for 2023, indicating robust growth expectations. Furthermore, the company has successfully increased its Medicare Advantage (MA) payer mix from approximately 9.2% in 2018 to around 16.5% by the first quarter of 2025, reflecting a significant shift in its business strategy that aligns with market demand. This combination of increasing revenue guidance and an expanding MA book of business positions Encompass Health favorably within the post-acute healthcare sector.

Bears say

Encompass Health Corp's outlook appears negative due to the anticipated challenges associated with its de novo and joint venture strategies, which may lead to increased construction and labor costs amid rising tariffs and competitive labor markets. The company could face difficulties in staffing new facilities, which is critical for achieving mature operating levels, potentially disrupting its earnings profile. Given these factors, there are significant risks that could impede the company's ability to meet projected financial targets, including its 2025 adjusted EBITDA goal of $1.245 billion.

Encompass Health (EHC) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Encompass Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Encompass Health (EHC) Forecast

Analysts have given Encompass Health (EHC) a Buy based on their latest research and market trends.

According to 7 analysts, Encompass Health (EHC) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $142.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $142.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Encompass Health (EHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.